Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jun 9, 2011

Premium

Title: microRNA Biomarkers for Human Breast and Lung Cancer

Patent Number: 7,955,848

Filed: April 2, 2007

Lead Inventor: Ethan Dmitrovsky, Dartmouth College

The invention, the patent's abstract states, “relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.”


Title: Compositions Comprising Inhibitors of RNA-Binding Proteins and Methods of Producing and Using the Same

Patent Number: 7,956,044

Filed: April 3, 2009

Lead Inventor: Courtney Houchen, University of Oklahoma

The invention, the patent's abstract states, comprises “compositions for inhibiting RNA binding proteins, as well as methods of producing and using same.”

The patent specifically claims siRNAs against Musashi-1.


Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Patent Number: 7,956,176

Filed: Aug. 4, 2006

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent's abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic-discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid ... capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”


Title: dsRNA Compositions and Methods for Treating HPV Infection

Patent Number: 7,956,177

Filed: March 23, 2007

Lead Inventor: John Benson, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for treating human papillomavirus infection,” the patent's abstract states. “The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of an HPV target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV target genes in a cell.”


Title: RNA Interference-Mediated Inhibition of GRB2-Associated Binding Protein Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,956,178

Filed: Dec. 17, 2009

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating GRB2-associated binding protein gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GRB2 associated binding protein gene expression and/or activity by RNA interference using small nucleic acid molecules. ...The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease (leukemia), inflammatory diseases or conditions, allergic diseases or conditions, or proliferative diseases or conditions.


Title: Targeted Polymer Bioconjugates

Application Number: 20110129921

Filed: May 13, 2009

Lead Inventor: Paul Johnson, PhaseRx

The invention, the patent application's abstract states, comprises a “polymer bioconjugate having [an] RNAi agent covalently coupled to the alpha or omega end of a pH-dependent membrane-destabilizing polymer.”


Title: Compositions and Methods for Inhibiting Expression of Factor V Leiden Mutant Gene

Application Number: 20110130443

Filed: Jan. 20, 2011

Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the factor V Leiden mutant gene comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the ... mutant gene,” the patent application's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the factor V Leiden mutant gene in a cell.”


Title: Treatment of Abnormal or Excessive Scars

Application Number: 20110130710

Filed: Dec. 22, 2008

Lead Inventor: David Lawrence Becker, University College London

The invention comprises “methods, compounds, compositions, kits, and articles of manufacture comprising anti-connexin polynucleotides for prevention and/or treatment of abnormal scars, including keloid scars, hypertrophic scars, atrophic scars, and widespread scars,” the patent application's abstract states.

The application specifically claims the administration of an siRNA or other RNAi compound to treat scarring.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.